ENHERTU® Shows Strong Clinical Activity in HER2+ Metastatic Breast Cancer with Brain Metastases
Results from the DESTINY-Breast12 phase 3b/4 trial reveal that ENHERTU® (trastuzumab deruxtecan) demonstrated significant clinical activity in HER2-positive metastatic breast cancer patients with brain metastases who had received up to…
LifestyledAI, Dongguk University, and UMUST R&D Partner to Drive Global AI and Healthcare Innovation
On August 28, 2024, Dongguk University Startup Technology Institute, LifestyledAI Co., Ltd., and UMUST R&D signed a joint MOU to collaborate on advancing global deep tech and healthcare initiatives. The…
Massive Bio and Foundation Medicine Partner to Enhance Cancer Clinical Trial Access
Massive Bio, an AI-powered clinical trial matching platform, and Foundation Medicine have announced a strategic partnership to expand patient access to advanced clinical trials. The collaboration combines Massive Bio’s patient-matching…
FDA Approves Ocrevus Zunovo™: First Twice-Yearly 10-Minute Injection for MS
Genentech, part of the Roche Group, announced that the U.S. FDA has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).…
Neuraptive Receives FDA Breakthrough Designation for NTX-001 and Updates on Peripheral Nerve Injury Treatment
Neuraptive Therapeutics, Inc. has announced that its therapy NTX-001 has received Breakthrough Therapy Designation from the FDA, which could accelerate its development for patients with peripheral nerve injuries that need…
ŌURA Acquires Veri to Enhance Metabolic Health Capabilities
ŌURA, the company behind the Oura Ring, has announced its acquisition of Veri, a Finnish firm specializing in personalized metabolic health. Veri, which partners with Oura to offer metabolic insights…
Viridian Therapeutics Prices Upsized Public Offering of Common and Preferred Stock
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotech firm specializing in developing treatments for rare and serious diseases, has announced the pricing of its public offering. The company will sell 10,666,600…
Spencer Health Solutions Earns ISO 27001 Certification
Spencer Health Solutions (SHS), a leader in intelligent medication management technology, has announced its achievement of ISO 27001:2022 certification. This esteemed accreditation highlights SHS’s dedication to safeguarding patient data and…
Signet Healthcare Sells Paragonix Technologies to Getinge
Signet Healthcare Partners (“Signet”) has announced the successful sale of its portfolio company, Paragonix Technologies (“Paragonix”), to global medical technology leader Getinge. Paragonix, renowned for its advancements in organ transplantation…
Contraline & Population Council Strike Deal for Innovative Male Contraceptive
Contraline, Inc., a clinical-stage biotechnology firm, has signed an exclusive option-to-license agreement with the Population Council for the Nestorone/Testosterone Transdermal Gel (NES/T) for male contraception. If the option is exercised,…
Vaxxas Launches Phase I Trial of H7N9 Vaccine with HD-MAP Technology
Vaxxas announced the start of a multi-center Phase I clinical trial for a vaccine targeting the pre-pandemic avian influenza strain H7N9, using its high-density microarray patch (HD-MAP) technology. Vaxxas has…
EORTC Expands Partnership with Medidata for Next Phase of Cancer Research
Medidata, a Dassault Systèmes brand and leader in clinical trial solutions for the life sciences industry, has announced a four-year extension of its partnership with the European Organisation for Research…